li001

Gastroesophageal cancers, though relatively uncommon in the U.S., cause significant morbidity and mortality worldwide. For early-stage gastric and gastroesophageal junction (GEJ) adenocarcinoma, the primary goal is cure, achieved through multimodality treatment. Landmark trials demonstrated the benefits of perioperative chemotherapy, such as the MAGIC trial’s pECF regimen, and neoadjuvant chemoradiotherapy, like the CROSS trial’s nCROSS regimen.

The COAST trial, a randomized phase 2 study, evaluated whether adding novel immunotherapies to durvalumab could improve outcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) who had completed chemoradiotherapy without progression. Patients received durvalumab alone, durvalumab plus oleclumab (anti-CD73), or durvalumab plus monalizumab (anti-NKG2A). Updated results showed enhanced activity with both

Prostate cancer treatment has advanced significantly, with approaches tailored to disease stage. For localized or early-stage disease, focal therapies aim to destroy only the cancerous area while sparing healthy tissue, reducing side effects like incontinence and erectile dysfunction. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, and radiofrequency ablation. Advanced radiation methods, such as intensity-modulated radiation therapy